Review



vegf a121  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Proteintech vegf a121
    Vegf A121, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+a121/EIF1+Fusion+Protein/pm41606331-657-2-19
    Average 94 stars, based on 1 article reviews
    vegf a121 - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    Staining:

    Article Title: GlycoRNA complexed with heparan sulfate regulates VEGF-A signalling.
    Article Snippet: For 9D5, 10E4 and 3G10 staining, 2.5 μg ml−1 9D5 (Absolute Antibody), 1 μg ml−1 anti-HS 10E4 (Amsbio), 1 μg ml−1 anti-HS 3G10 (Amsbio) and anti-VEGF (R&D Systems) were precomplexed with 1.25 μg ml−1 of goat anti-rabbit AF647 secondary antibody (Thermo Fisher Scientific), 0.5 μg ml−1 of goat anti-mouse AF647 secondary antibody (Thermo Fisher Scientific) or donkey anti-goat IgG AF647 (Thermo Fisher Scientific) secondary antibodies in FACS buffer for 45 min on ice, separately. .. For VEGF-A165, VEGF-A121 and VEGFR2 staining, 1 μg ml −1 of anti-VEGF-A165 (R&D Systems), 1 μg ml−1 of anti-VEGF-A (Proteintech), and 1 μg ml−1 anti-VEGFR2 (R&D Systems) were precomplexed with 0.5 μg ml−1 of goat anti-rabbit AF647 secondary antibody and donkey anti-goat AF647 secondary antibody (Thermo Fisher Scientific). ..



    Similar Products

    94
    Proteintech vegf a121
    Vegf A121, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+a121/EIF1+Fusion+Protein/pm41606331-657-2-19
    Average 94 stars, based on 1 article reviews
    vegf a121 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc recombinant human vegf a121
    Recombinant Human Vegf A121, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+a121/Human+VEGF-165+Recombinant+Protein/pm39700124-58-6-11
    Average 94 stars, based on 1 article reviews
    recombinant human vegf a121 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    92
    Sino Biological hvegf a121
    <t>VEGF-A121,</t> VEGF-A165, and VEGF-A concentrations in plasma ( a - c ) and in serum ( d - f ) were measured pre- and post-bevacizumab administration, showing that only VEGF-A121 is a clear marker of bevacizumab therapy in both plasma and serum. a Plasma VEGF-A121 exhibited a median increase of 808.6 pg/mL, 95% CI [748.7, 874.0], p = 0.00049. b Plasma VEGF-A165 concentration was below the high-accuracy threshold, both pre- and post-administration, and exhibited a statistically insignificant median change of 0 pg/mL, 95% CI [–1.7, –1.6], p = 0.3125. c Plasma VEGF-A exhibited a median change of 156.9 pg/mL, 95% CI [126.8, 190.0], p = 0.00026. d Serum VEGF-A121 exhibited a median increase of 860.8 pg/mL, 95% CI [468.5, 1128.9], p = 0.0024. e Serum VEGF-A165 exhibited a medium change of –73.8 pg/mL, 95% CI [–149.4, –10.2], p = 0.0034, with 10 of 12 (83.3%) of the post-bevacizumab concentrations falling below the high-accuracy threshold of 38 pg/mL. f Serum VEGF-A exhibited a median change of –86.1 pg/mL, 95% CI [–545.4, 88.74], p = 0.1763.
    Hvegf A121, supplied by Sino Biological, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+a121/Human+VEGF%2FVEGFA%2FVEGF121+transcript+variant+6+Gene+ORF+cDNA+clone+expression+plasmid%2C+N-Flag+tag/pmc11658504-69-3-11
    Average 92 stars, based on 1 article reviews
    hvegf a121 - by Bioz Stars, 2026-11
    92/100 stars
      Buy from Supplier

    93
    R&D Systems germany vegf a121 165 206 23410 apc monoclonal mouse igg2a r d systems
    <t>VEGF-A121,</t> VEGF-A165, and VEGF-A concentrations in plasma ( a - c ) and in serum ( d - f ) were measured pre- and post-bevacizumab administration, showing that only VEGF-A121 is a clear marker of bevacizumab therapy in both plasma and serum. a Plasma VEGF-A121 exhibited a median increase of 808.6 pg/mL, 95% CI [748.7, 874.0], p = 0.00049. b Plasma VEGF-A165 concentration was below the high-accuracy threshold, both pre- and post-administration, and exhibited a statistically insignificant median change of 0 pg/mL, 95% CI [–1.7, –1.6], p = 0.3125. c Plasma VEGF-A exhibited a median change of 156.9 pg/mL, 95% CI [126.8, 190.0], p = 0.00026. d Serum VEGF-A121 exhibited a median increase of 860.8 pg/mL, 95% CI [468.5, 1128.9], p = 0.0024. e Serum VEGF-A165 exhibited a medium change of –73.8 pg/mL, 95% CI [–149.4, –10.2], p = 0.0034, with 10 of 12 (83.3%) of the post-bevacizumab concentrations falling below the high-accuracy threshold of 38 pg/mL. f Serum VEGF-A exhibited a median change of –86.1 pg/mL, 95% CI [–545.4, 88.74], p = 0.1763.
    Germany Vegf A121 165 206 23410 Apc Monoclonal Mouse Igg2a R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+a121/Mouse+IgG2A+APC-conjugated+Antibody/pmc10956503__crc___22___0366___s05-0-61-68
    Average 93 stars, based on 1 article reviews
    germany vegf a121 165 206 23410 apc monoclonal mouse igg2a r d systems - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    90
    PeproTech human vegf-a121
    <t>VEGF-A121,</t> VEGF-A165, and VEGF-A concentrations in plasma ( a - c ) and in serum ( d - f ) were measured pre- and post-bevacizumab administration, showing that only VEGF-A121 is a clear marker of bevacizumab therapy in both plasma and serum. a Plasma VEGF-A121 exhibited a median increase of 808.6 pg/mL, 95% CI [748.7, 874.0], p = 0.00049. b Plasma VEGF-A165 concentration was below the high-accuracy threshold, both pre- and post-administration, and exhibited a statistically insignificant median change of 0 pg/mL, 95% CI [–1.7, –1.6], p = 0.3125. c Plasma VEGF-A exhibited a median change of 156.9 pg/mL, 95% CI [126.8, 190.0], p = 0.00026. d Serum VEGF-A121 exhibited a median increase of 860.8 pg/mL, 95% CI [468.5, 1128.9], p = 0.0024. e Serum VEGF-A165 exhibited a medium change of –73.8 pg/mL, 95% CI [–149.4, –10.2], p = 0.0034, with 10 of 12 (83.3%) of the post-bevacizumab concentrations falling below the high-accuracy threshold of 38 pg/mL. f Serum VEGF-A exhibited a median change of –86.1 pg/mL, 95% CI [–545.4, 88.74], p = 0.1763.
    Human Vegf A121, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+a121/human+vegf+a121/us11732036-1021-6-8
    Average 90 stars, based on 1 article reviews
    human vegf-a121 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    PeproTech vegf-a121
    <t>VEGF-A121,</t> VEGF-A165, and VEGF-A concentrations in plasma ( a - c ) and in serum ( d - f ) were measured pre- and post-bevacizumab administration, showing that only VEGF-A121 is a clear marker of bevacizumab therapy in both plasma and serum. a Plasma VEGF-A121 exhibited a median increase of 808.6 pg/mL, 95% CI [748.7, 874.0], p = 0.00049. b Plasma VEGF-A165 concentration was below the high-accuracy threshold, both pre- and post-administration, and exhibited a statistically insignificant median change of 0 pg/mL, 95% CI [–1.7, –1.6], p = 0.3125. c Plasma VEGF-A exhibited a median change of 156.9 pg/mL, 95% CI [126.8, 190.0], p = 0.00026. d Serum VEGF-A121 exhibited a median increase of 860.8 pg/mL, 95% CI [468.5, 1128.9], p = 0.0024. e Serum VEGF-A165 exhibited a medium change of –73.8 pg/mL, 95% CI [–149.4, –10.2], p = 0.0034, with 10 of 12 (83.3%) of the post-bevacizumab concentrations falling below the high-accuracy threshold of 38 pg/mL. f Serum VEGF-A exhibited a median change of –86.1 pg/mL, 95% CI [–545.4, 88.74], p = 0.1763.
    Vegf A121, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+a121/human+vegf+a121/us11732029-1003-0-28
    Average 90 stars, based on 1 article reviews
    vegf-a121 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    PeproTech recombinant human vegf-a121
    <t>VEGF-A121,</t> VEGF-A165, and VEGF-A concentrations in plasma ( a - c ) and in serum ( d - f ) were measured pre- and post-bevacizumab administration, showing that only VEGF-A121 is a clear marker of bevacizumab therapy in both plasma and serum. a Plasma VEGF-A121 exhibited a median increase of 808.6 pg/mL, 95% CI [748.7, 874.0], p = 0.00049. b Plasma VEGF-A165 concentration was below the high-accuracy threshold, both pre- and post-administration, and exhibited a statistically insignificant median change of 0 pg/mL, 95% CI [–1.7, –1.6], p = 0.3125. c Plasma VEGF-A exhibited a median change of 156.9 pg/mL, 95% CI [126.8, 190.0], p = 0.00026. d Serum VEGF-A121 exhibited a median increase of 860.8 pg/mL, 95% CI [468.5, 1128.9], p = 0.0024. e Serum VEGF-A165 exhibited a medium change of –73.8 pg/mL, 95% CI [–149.4, –10.2], p = 0.0034, with 10 of 12 (83.3%) of the post-bevacizumab concentrations falling below the high-accuracy threshold of 38 pg/mL. f Serum VEGF-A exhibited a median change of –86.1 pg/mL, 95% CI [–545.4, 88.74], p = 0.1763.
    Recombinant Human Vegf A121, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+a121/human+vegf+a121/us11732029-1052-12-14
    Average 90 stars, based on 1 article reviews
    recombinant human vegf-a121 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    VEGF-A121, VEGF-A165, and VEGF-A concentrations in plasma ( a - c ) and in serum ( d - f ) were measured pre- and post-bevacizumab administration, showing that only VEGF-A121 is a clear marker of bevacizumab therapy in both plasma and serum. a Plasma VEGF-A121 exhibited a median increase of 808.6 pg/mL, 95% CI [748.7, 874.0], p = 0.00049. b Plasma VEGF-A165 concentration was below the high-accuracy threshold, both pre- and post-administration, and exhibited a statistically insignificant median change of 0 pg/mL, 95% CI [–1.7, –1.6], p = 0.3125. c Plasma VEGF-A exhibited a median change of 156.9 pg/mL, 95% CI [126.8, 190.0], p = 0.00026. d Serum VEGF-A121 exhibited a median increase of 860.8 pg/mL, 95% CI [468.5, 1128.9], p = 0.0024. e Serum VEGF-A165 exhibited a medium change of –73.8 pg/mL, 95% CI [–149.4, –10.2], p = 0.0034, with 10 of 12 (83.3%) of the post-bevacizumab concentrations falling below the high-accuracy threshold of 38 pg/mL. f Serum VEGF-A exhibited a median change of –86.1 pg/mL, 95% CI [–545.4, 88.74], p = 0.1763.

    Journal: PLOS ONE

    Article Title: Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration

    doi: 10.1371/journal.pone.0316035

    Figure Lengend Snippet: VEGF-A121, VEGF-A165, and VEGF-A concentrations in plasma ( a - c ) and in serum ( d - f ) were measured pre- and post-bevacizumab administration, showing that only VEGF-A121 is a clear marker of bevacizumab therapy in both plasma and serum. a Plasma VEGF-A121 exhibited a median increase of 808.6 pg/mL, 95% CI [748.7, 874.0], p = 0.00049. b Plasma VEGF-A165 concentration was below the high-accuracy threshold, both pre- and post-administration, and exhibited a statistically insignificant median change of 0 pg/mL, 95% CI [–1.7, –1.6], p = 0.3125. c Plasma VEGF-A exhibited a median change of 156.9 pg/mL, 95% CI [126.8, 190.0], p = 0.00026. d Serum VEGF-A121 exhibited a median increase of 860.8 pg/mL, 95% CI [468.5, 1128.9], p = 0.0024. e Serum VEGF-A165 exhibited a medium change of –73.8 pg/mL, 95% CI [–149.4, –10.2], p = 0.0034, with 10 of 12 (83.3%) of the post-bevacizumab concentrations falling below the high-accuracy threshold of 38 pg/mL. f Serum VEGF-A exhibited a median change of –86.1 pg/mL, 95% CI [–545.4, 88.74], p = 0.1763.

    Article Snippet: Expression plasmids for hVEGF-A121 (#HG10008-NF) and hVEGF-A165 (#RC229662) were purchased from Sino Biological (Beijing, China) and OriGene Technologies (Rockville, MD), respectively.

    Techniques: Marker, Concentration Assay

    Concentrations of VEGF-A121, VEGF-A165, and VEGF-A in the platelet lysates, showing that the amounts of VEGF-A and its isoforms in platelets do not change to a statistically significant degree between pre- and post-bevacizumab administration. a VEGF-A121 exhibited a median change of –0.03 pg/10 6 platelets, 95% CI [–0.08, 0.14], p = 0.625. b VEGF-A165 exhibited a median change of –0.02 pg/10 6 platelets, 95% CI [–0.004, 0.129], p = 0.250. c VEGF-A exhibited a median change of –0.117 pg/10 6 platelets, 95% CI [–0.374, 0.301], p = 0.556.

    Journal: PLOS ONE

    Article Title: Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration

    doi: 10.1371/journal.pone.0316035

    Figure Lengend Snippet: Concentrations of VEGF-A121, VEGF-A165, and VEGF-A in the platelet lysates, showing that the amounts of VEGF-A and its isoforms in platelets do not change to a statistically significant degree between pre- and post-bevacizumab administration. a VEGF-A121 exhibited a median change of –0.03 pg/10 6 platelets, 95% CI [–0.08, 0.14], p = 0.625. b VEGF-A165 exhibited a median change of –0.02 pg/10 6 platelets, 95% CI [–0.004, 0.129], p = 0.250. c VEGF-A exhibited a median change of –0.117 pg/10 6 platelets, 95% CI [–0.374, 0.301], p = 0.556.

    Article Snippet: Expression plasmids for hVEGF-A121 (#HG10008-NF) and hVEGF-A165 (#RC229662) were purchased from Sino Biological (Beijing, China) and OriGene Technologies (Rockville, MD), respectively.

    Techniques:

    Bevacizumab absorbed VEGF-A121 and VEGF-A165 in a dose dependent manner. a and b show the results of bevacizumab addition to rhVEGF-A. a Bevacizumab was added at 1, 10, and 100 μg/mL to rhVEGF-A121, adjusted to a concentration of 100 ng/mL. After the one-way ANOVA test, a test of linear trend between column means and column order from left to right was performed for multiple comparisons, and a linear trend was observed between VEGF-A121 and bevacizumab concentrations (ANOVA: p < 0.0001; test for trend: p < 0.0001). b Similar experiments were performed using VEGF-A165 (ANOVA: p < 0.0001; test for trend: p < 0.0001). c and d show the results of bevacizumab addition to the culture medium of HEK293 cells transfected with VEGF-A. c HEK293 cells were transfected with VEGF-A121 and cultured in a medium containing 1, 10, or 100 μg/mL bevacizumab, and in a culture medium without bevacizumab (control). The culture medium was collected, and VEGF-A121 concentrations were measured. The same test was performed, and a linear trend was observed (ANOVA, p < 0.0001; test for trend, p < 0.0001). d The same experiment was performed for VEGF-A165 (ANOVA: p < 0.0001; test for trend: p < 0.0001).

    Journal: PLOS ONE

    Article Title: Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration

    doi: 10.1371/journal.pone.0316035

    Figure Lengend Snippet: Bevacizumab absorbed VEGF-A121 and VEGF-A165 in a dose dependent manner. a and b show the results of bevacizumab addition to rhVEGF-A. a Bevacizumab was added at 1, 10, and 100 μg/mL to rhVEGF-A121, adjusted to a concentration of 100 ng/mL. After the one-way ANOVA test, a test of linear trend between column means and column order from left to right was performed for multiple comparisons, and a linear trend was observed between VEGF-A121 and bevacizumab concentrations (ANOVA: p < 0.0001; test for trend: p < 0.0001). b Similar experiments were performed using VEGF-A165 (ANOVA: p < 0.0001; test for trend: p < 0.0001). c and d show the results of bevacizumab addition to the culture medium of HEK293 cells transfected with VEGF-A. c HEK293 cells were transfected with VEGF-A121 and cultured in a medium containing 1, 10, or 100 μg/mL bevacizumab, and in a culture medium without bevacizumab (control). The culture medium was collected, and VEGF-A121 concentrations were measured. The same test was performed, and a linear trend was observed (ANOVA, p < 0.0001; test for trend, p < 0.0001). d The same experiment was performed for VEGF-A165 (ANOVA: p < 0.0001; test for trend: p < 0.0001).

    Article Snippet: Expression plasmids for hVEGF-A121 (#HG10008-NF) and hVEGF-A165 (#RC229662) were purchased from Sino Biological (Beijing, China) and OriGene Technologies (Rockville, MD), respectively.

    Techniques: Concentration Assay, Transfection, Cell Culture, Control

    Addition of rhVEGF-A (-121 or-165; 1,000 pg/mL or 10,000 pg/mL) to plasma samples pre- and post-bevacizumab administration, and the magnitude of change associated with the addition was calculated by subtracting the concentration in plasma samples without rhVEGF-A from the concentration in plasma samples with rhVEGF-A added. a Plasma samples pre-bevacizumab administration showed an increase in VEGF-A121 concentration (mean ± SD: 655 ± 44 pg/mL) corresponding to the addition of 1,000 pg/mL of rhVEGF-A121; plasma samples post-bevacizumab administration showed no increase in the concentration corresponding to the addition (mean ± SD: 15 ± 18 pg/mL). b Similarly, the addition of 1,000 pg/mL of rhVEGF-A165 increased the concentration of VEGF-A165 in plasma samples pre-bevacizumab administration (mean ± SD: 670 ± 102 pg/mL), whereas the increase in concentration was negligible in plasma samples post-bevacizumab administration (mean ± SD: 38 ± 9 pg/mL). c Addition of 10,000 pg/mL rhVEGF-A121 increased the concentration of VEGF-A121 in plasma samples pre-bevacizumab administration (mean ± SD: 4,624 ± 1,500 pg/mL), whereas the increase in concentration was negligible in plasma samples post-bevacizumab administration (mean ± SD: 96 ± 92 pg/mL). d Addition of 10,000 pg/mL rhVEGF-A165 increased the concentration of VEGF-A165 in plasma samples pre-bevacizumab administration (mean ± SD: 3,121 ± 1,236 pg/mL), whereas the increase in concentration was negligible in plasma samples post-bevacizumab administration (mean ± SD: 409 ± 134 pg/mL).

    Journal: PLOS ONE

    Article Title: Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration

    doi: 10.1371/journal.pone.0316035

    Figure Lengend Snippet: Addition of rhVEGF-A (-121 or-165; 1,000 pg/mL or 10,000 pg/mL) to plasma samples pre- and post-bevacizumab administration, and the magnitude of change associated with the addition was calculated by subtracting the concentration in plasma samples without rhVEGF-A from the concentration in plasma samples with rhVEGF-A added. a Plasma samples pre-bevacizumab administration showed an increase in VEGF-A121 concentration (mean ± SD: 655 ± 44 pg/mL) corresponding to the addition of 1,000 pg/mL of rhVEGF-A121; plasma samples post-bevacizumab administration showed no increase in the concentration corresponding to the addition (mean ± SD: 15 ± 18 pg/mL). b Similarly, the addition of 1,000 pg/mL of rhVEGF-A165 increased the concentration of VEGF-A165 in plasma samples pre-bevacizumab administration (mean ± SD: 670 ± 102 pg/mL), whereas the increase in concentration was negligible in plasma samples post-bevacizumab administration (mean ± SD: 38 ± 9 pg/mL). c Addition of 10,000 pg/mL rhVEGF-A121 increased the concentration of VEGF-A121 in plasma samples pre-bevacizumab administration (mean ± SD: 4,624 ± 1,500 pg/mL), whereas the increase in concentration was negligible in plasma samples post-bevacizumab administration (mean ± SD: 96 ± 92 pg/mL). d Addition of 10,000 pg/mL rhVEGF-A165 increased the concentration of VEGF-A165 in plasma samples pre-bevacizumab administration (mean ± SD: 3,121 ± 1,236 pg/mL), whereas the increase in concentration was negligible in plasma samples post-bevacizumab administration (mean ± SD: 409 ± 134 pg/mL).

    Article Snippet: Expression plasmids for hVEGF-A121 (#HG10008-NF) and hVEGF-A165 (#RC229662) were purchased from Sino Biological (Beijing, China) and OriGene Technologies (Rockville, MD), respectively.

    Techniques: Concentration Assay

    Serum samples pre-bevacizumab administration were treated with or without bevacizumab (2 μg/mL). Serum samples after bevacizumab treatment with an additional 2, 20, or 200 μg/mL of bevacizumab were compared to control samples without bevacizumab, indicating that free VEGF-A121 remained even at high doses of bevacizumab addition. a VEGF-A121 exhibited a change of –173.2, 95% CI [–322.8, –96.3], p = 0.00049, where the addition of 2 μg/mL bevacizumab markedly reduced the VEGF-A121 concentration to a median of 26.9 pg/mL, with a range of 67.3 pg/mL that partly fell below the high-accuracy threshold of 38 pg/mL. b VEGF-A165 concentrations exhibited a change of –46.4, 95% CI [–101.4, –16.6], p = 0.0015, driven down to a median of 2.9 pg/mL with a range of 14.12 pg/mL that is entirely below the high-accuracy threshold. c Further addition of bevacizumab to serum samples post-bevacizumab administration significantly decreased VEGF-A121 levels in samples to which 20 and 200 μg/mL bevacizumab was added (ANOVA: p < 0.0001; Dunnett’s multiple comparisons test: +2 μg/mL, p = 0.7096 vs control; +20 μg/mL, p = 0.0107 vs control; +200 μg/mL, p < 0.0001 vs control). d VEGF-A165 concentrations were low in serum samples post-bevacizumab administration and remained low after further addition of bevacizumab. e The percent change in VEGF-A121 concentration with the addition of any (2, 20, or 200 μg/mL) concentration of bevacizumab to serum samples post-bevacizumab administration was significantly less than the percent change in VEGF-A121 concentration with the addition of 2 μg/mL concentration of bevacizumab to serum samples pre-bevacizumab administration (ANOVA: p < 0.0001; Dunnett’s multiple comparisons test: Post+2 μg/mL, p < 0.0001 vs Pre+2 μg/mL; Post +20 μg/mL, p < 0.0001 vs Pre+2 μg/mL; +200 μg/mL, p < 0.0001 vs Pre+2 μg/mL).

    Journal: PLOS ONE

    Article Title: Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration

    doi: 10.1371/journal.pone.0316035

    Figure Lengend Snippet: Serum samples pre-bevacizumab administration were treated with or without bevacizumab (2 μg/mL). Serum samples after bevacizumab treatment with an additional 2, 20, or 200 μg/mL of bevacizumab were compared to control samples without bevacizumab, indicating that free VEGF-A121 remained even at high doses of bevacizumab addition. a VEGF-A121 exhibited a change of –173.2, 95% CI [–322.8, –96.3], p = 0.00049, where the addition of 2 μg/mL bevacizumab markedly reduced the VEGF-A121 concentration to a median of 26.9 pg/mL, with a range of 67.3 pg/mL that partly fell below the high-accuracy threshold of 38 pg/mL. b VEGF-A165 concentrations exhibited a change of –46.4, 95% CI [–101.4, –16.6], p = 0.0015, driven down to a median of 2.9 pg/mL with a range of 14.12 pg/mL that is entirely below the high-accuracy threshold. c Further addition of bevacizumab to serum samples post-bevacizumab administration significantly decreased VEGF-A121 levels in samples to which 20 and 200 μg/mL bevacizumab was added (ANOVA: p < 0.0001; Dunnett’s multiple comparisons test: +2 μg/mL, p = 0.7096 vs control; +20 μg/mL, p = 0.0107 vs control; +200 μg/mL, p < 0.0001 vs control). d VEGF-A165 concentrations were low in serum samples post-bevacizumab administration and remained low after further addition of bevacizumab. e The percent change in VEGF-A121 concentration with the addition of any (2, 20, or 200 μg/mL) concentration of bevacizumab to serum samples post-bevacizumab administration was significantly less than the percent change in VEGF-A121 concentration with the addition of 2 μg/mL concentration of bevacizumab to serum samples pre-bevacizumab administration (ANOVA: p < 0.0001; Dunnett’s multiple comparisons test: Post+2 μg/mL, p < 0.0001 vs Pre+2 μg/mL; Post +20 μg/mL, p < 0.0001 vs Pre+2 μg/mL; +200 μg/mL, p < 0.0001 vs Pre+2 μg/mL).

    Article Snippet: Expression plasmids for hVEGF-A121 (#HG10008-NF) and hVEGF-A165 (#RC229662) were purchased from Sino Biological (Beijing, China) and OriGene Technologies (Rockville, MD), respectively.

    Techniques: Control, Concentration Assay

    Serum samples pre- and post-bevacizumab administration were immunoprecipitated to remove the VEGF-A–bevacizumab complex and the isoform concentrations were measured in the remaining serum samples, showing that VEGF-A121 post administration exhibited the most substantial change. a Pre-administration, VEGF-A121 exhibited a median change of –37.3 pg/mL, 95% CI [–54.6, –16.0], p = 0.00049. b Pre-administration, VEGF-A165 exhibited a statistically insignificant median change of –18.1 pg/mL, 95% CI [–34.2, 7.5], p = 0.1475 c Post-administration, VEGF-A121 exhibited a substantial median change of –771.8 pg/mL, 95% CI [–970.9, –567.5], p = 0.00049. d Post-administration VEGF-A165 exhibited a small median change of –12.5 pg/mL, 95% CI [–23.4, –6.1], p = 0.0210. e Due to the possibility of nonspecific removal of VEGF-A using immunoprecipitation, the rate of change in VEGF-A121 concentration due to immunoprecipitation was compared pre- and post-bevacizumab administration and was reduced more by immunoprecipitation in specimens post-bevacizumab administration.

    Journal: PLOS ONE

    Article Title: Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration

    doi: 10.1371/journal.pone.0316035

    Figure Lengend Snippet: Serum samples pre- and post-bevacizumab administration were immunoprecipitated to remove the VEGF-A–bevacizumab complex and the isoform concentrations were measured in the remaining serum samples, showing that VEGF-A121 post administration exhibited the most substantial change. a Pre-administration, VEGF-A121 exhibited a median change of –37.3 pg/mL, 95% CI [–54.6, –16.0], p = 0.00049. b Pre-administration, VEGF-A165 exhibited a statistically insignificant median change of –18.1 pg/mL, 95% CI [–34.2, 7.5], p = 0.1475 c Post-administration, VEGF-A121 exhibited a substantial median change of –771.8 pg/mL, 95% CI [–970.9, –567.5], p = 0.00049. d Post-administration VEGF-A165 exhibited a small median change of –12.5 pg/mL, 95% CI [–23.4, –6.1], p = 0.0210. e Due to the possibility of nonspecific removal of VEGF-A using immunoprecipitation, the rate of change in VEGF-A121 concentration due to immunoprecipitation was compared pre- and post-bevacizumab administration and was reduced more by immunoprecipitation in specimens post-bevacizumab administration.

    Article Snippet: Expression plasmids for hVEGF-A121 (#HG10008-NF) and hVEGF-A165 (#RC229662) were purchased from Sino Biological (Beijing, China) and OriGene Technologies (Rockville, MD), respectively.

    Techniques: Immunoprecipitation, Concentration Assay

    The left panel shows the condition pre-bevacizumab administration. VEGF-A121 is present at high concentrations in the tumor stroma; VEGF-A165 binds to the interstitial matrix and vessel walls for binding to HSPG. Right panel shows the condition post-bevacizumab administration. Free VEGF-A121 in the tumor stroma and free VEGF-A121 in the plasma reach an equal concentration; thus, the plasma VEGF-A121 concentration increases and the VEGF-A121 concentration in the tumor stroma decreases.

    Journal: PLOS ONE

    Article Title: Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration

    doi: 10.1371/journal.pone.0316035

    Figure Lengend Snippet: The left panel shows the condition pre-bevacizumab administration. VEGF-A121 is present at high concentrations in the tumor stroma; VEGF-A165 binds to the interstitial matrix and vessel walls for binding to HSPG. Right panel shows the condition post-bevacizumab administration. Free VEGF-A121 in the tumor stroma and free VEGF-A121 in the plasma reach an equal concentration; thus, the plasma VEGF-A121 concentration increases and the VEGF-A121 concentration in the tumor stroma decreases.

    Article Snippet: Expression plasmids for hVEGF-A121 (#HG10008-NF) and hVEGF-A165 (#RC229662) were purchased from Sino Biological (Beijing, China) and OriGene Technologies (Rockville, MD), respectively.

    Techniques: Binding Assay, Concentration Assay